# Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas

> **NCT00374699** · PHASE1,PHASE2 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 55 (estimated)

## Conditions studied

- Peripheral T-Cell Lymphomas
- Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Velcade

## Key facts

- **NCT ID:** NCT00374699
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2009-09
- **Final completion:** 2009-10
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2009-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00374699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00374699, "Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00374699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*